GP KFPs / SAQs · palliative-care
Palliative symptom control in the community — KFP-style written assessment
KFP-style staged scenarios on palliative symptom control: opioid selection by renal function, breakthrough dosing calculation, antiemetic selection by receptor mechanism, laxative co-prescribing, terminal agitation management, and syringe driver initiation.
On this page
Study tools
Target exams
RACGP KFPRACGP AKTMRCGP AKT
Prompt
Palliative symptom control: match the opioid to the kidney, calculate the breakthrough dose, select the right antiemetic, and never forget the laxative
KFP 1 (10 marks)
A 62-year-old woman with metastatic breast cancer has moderate-to-severe pain. Her eGFR is 22 mL/min. She is currently on paracetamol alone. [1]
- Which opioid class should you avoid and why? (4) [1]
- What should you prescribe instead? (3) [1]
- What breakthrough dose rule applies? (3)
Model answers
- Avoid morphine and codeine. Morphine produces active metabolites M6G (analgesic) and M3G (neuroexcitatory) that are cleared renally; at eGFR 22 they accumulate causing sedation, myoclonus and respiratory depression. Codeine is also renally cleared with active metabolites. [1]
- Prescribe a fentanyl patch for background analgesia plus low-dose subcutaneous fentanyl PRN for breakthrough. Buprenorphine patch is an alternative. Both undergo hepatic metabolism without active renally-cleared metabolites. [1]
- Breakthrough dose equals one-sixth of the total 24-hour opioid dose, given PRN by the same route. Two or more PRN doses in 24 hours means the background dose should be increased. [1]
References4ShowHide
- [1]King S, Forbes K, Hanks GW, Ferro CJ, Chambers EJ A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. Palliat Med, 2011.PMID 21708859
- [2]Chamberlain BH, Rhiner M, Slatkin NE, Stambler N, Israel RJ Methylnaltrexone Treatment for Opioid-Induced Constipation in Patients with and without Cancer: Effect of Initial Dose. J Pain Res, 2023.PMID 37533563
- [4]Smallwood NE, Pascoe A, Wijsenbeek M, Russell AM, Holland AE, et al. Opioids for the palliation of symptoms in people with serious respiratory illness: a systematic review and meta-analysis. Eur Respir Rev, 2024.PMID 39384304
- [5]Pereira RA, Barcellos G, Lenz G, Christmann A, de Mello MAJ, et al. Fan Therapy for Dyspnea in Palliative and Supportive Care: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Respir Care, 2026.PMID 41761933